LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

BioCryst Pharmaceuticals Inc

Fechado

SetorSaúde

10.35 -0.48

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.18

Máximo

10.45

Indicadores-chave

By Trading Economics

Rendimento

27M

32K

Vendas

14M

146M

EPS

0

Margem de lucro

0.022

Funcionários

580

EBITDA

22M

21M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+55.04% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

473M

2.3B

Abertura anterior

10.83

Fecho anterior

10.35

Sentimento de Notícias

By Acuity

67%

33%

344 / 380 Ranking em Healthcare

BioCryst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de jun. de 2025, 20:41 UTC

Ganhos

Adobe Raises Outlook After 2Q Sales Beat

12 de jun. de 2025, 23:50 UTC

Ganhos

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12 de jun. de 2025, 23:50 UTC

Ganhos

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12 de jun. de 2025, 23:50 UTC

Ganhos

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12 de jun. de 2025, 23:48 UTC

Conversa de Mercado

Gold Steady Amid Geopolitical Risks -- Market Talk

12 de jun. de 2025, 23:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

12 de jun. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12 de jun. de 2025, 21:26 UTC

Ganhos

Friedman Industries 4Q Sales $129.2M >FRD

12 de jun. de 2025, 21:25 UTC

Ganhos

Friedman Industries 4Q EPS 76c >FRD

12 de jun. de 2025, 21:11 UTC

Ganhos

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 de jun. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de jun. de 2025, 20:31 UTC

Ganhos

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 de jun. de 2025, 20:30 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12 de jun. de 2025, 20:15 UTC

Ganhos

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12 de jun. de 2025, 20:15 UTC

Ganhos

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12 de jun. de 2025, 20:14 UTC

Ganhos

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12 de jun. de 2025, 20:07 UTC

Ganhos

Adobe Raises FY25 Rev and EPS Targets

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Net $1.69B >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q EPS $3.94 >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Rev $5.87B >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12 de jun. de 2025, 20:05 UTC

Ganhos

Adobe 2Q Adj EPS $5.06 >ADBE

Comparação entre Pares

Variação de preço

BioCryst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

55.04% parte superior

Previsão para 12 meses

Média 16.45 USD  55.04%

Máximo 30 USD

Mínimo 11 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

10

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

344 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.